Why the study?
Do single RAAS-blocking agents reduce mortality or delay ESKD in adult patients with diabetes and non-dialysis CKD stages 3-5?
Population
9 RCTs pooling 9,797 adult patients with diabetes mellitus and non-dialysis chronic kidney disease stages 3-5.
Comparison
Single renin-angiotensin-aldosterone… vs Placebo or alternative antihypertensive agents.
Design
Meta-analysis
Follow-up
at least 6 months
Authors
Loading...
May not support preferential RAAS blockade in diabetic CKD stages 3-5; challenges presumed superiority and leaves optimal therapy open.
Do single RAAS-blocking agents reduce mortality or delay ESKD in adult patients with diabetes and non-dialysis CKD stages 3-5?
In adults with diabetes and advanced CKD, RAAS blockade does not confer a clear survival advantage but reduces the risk of needing renal replacement therapy or doubling of serum creatinine.
Nistor et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: